M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
FRA:M12 - Deutsche Boerse Ag - DE000A0STSQ8 - Common Stock - Currency: EUR
Taking everything into account, M12 scores 7 out of 10 in our fundamental rating. M12 was compared to 24 industry peers in the Health Care Providers & Services industry. M12 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. M12 is not overvalued while it is showing excellent growth. This is an interesting combination. This makes M12 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year M12 was profitable.
In the past year M12 had a positive cash flow from operations.
In the past 5 years M12 has always been profitable.
M12 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
M12 has a Return On Assets of 8.27%. This is amongst the best in the industry. M12 outperforms 95.83% of its industry peers.
M12 has a better Return On Equity (15.32%) than 79.17% of its industry peers.
M12's Return On Invested Capital of 10.98% is amongst the best of the industry. M12 outperforms 95.83% of its industry peers.
M12 had an Average Return On Invested Capital over the past 3 years of 5.33%. This is in line with the industry average of 5.69%.
The 3 year average ROIC (5.33%) for M12 is below the current ROIC(10.98%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.27% | ||
| ROE | 15.32% | ||
| ROIC | 10.98% |
ROA(3y)3.84%
ROA(5y)5.12%
ROE(3y)7.69%
ROE(5y)9.05%
ROIC(3y)5.33%
ROIC(5y)5.06%
1.3 Margins
M12 has a Profit Margin of 5.03%. This is in the better half of the industry: M12 outperforms 79.17% of its industry peers.
M12's Profit Margin has declined in the last couple of years.
The Operating Margin of M12 (6.87%) is better than 62.50% of its industry peers.
In the last couple of years the Operating Margin of M12 has declined.
M12 has a Gross Margin of 17.41%. This is comparable to the rest of the industry: M12 outperforms 45.83% of its industry peers.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.87% | ||
| PM (TTM) | 5.03% | ||
| GM | 17.41% |
OM growth 3Y19.76%
OM growth 5Y-14.29%
PM growth 3Y-8.75%
PM growth 5Y-20.36%
GM growth 3Y-11.67%
GM growth 5Y-14.71%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so M12 is still creating some value.
Compared to 1 year ago, M12 has more shares outstanding
The number of shares outstanding for M12 has been increased compared to 5 years ago.
M12 has a better debt/assets ratio than last year.
2.2 Solvency
M12 has an Altman-Z score of 4.97. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
M12 has a better Altman-Z score (4.97) than 100.00% of its industry peers.
The Debt to FCF ratio of M12 is 0.60, which is an excellent value as it means it would take M12, only 0.60 years of fcf income to pay off all of its debts.
M12's Debt to FCF ratio of 0.60 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
M12 has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of M12 (0.07) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 4.97 |
ROIC/WACC1.53
WACC7.17%
2.3 Liquidity
A Current Ratio of 1.76 indicates that M12 should not have too much problems paying its short term obligations.
The Current ratio of M12 (1.76) is better than 83.33% of its industry peers.
M12 has a Quick Ratio of 1.10. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of M12 (1.10) is better than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 163.63%, which is quite impressive.
The Earnings Per Share has been growing slightly by 5.87% on average over the past years.
M12 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.05%.
The Revenue has been growing by 37.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)163.63%
EPS 3Y12.51%
EPS 5Y5.87%
EPS Q2Q%189.66%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y25.61%
Revenue growth 5Y37.14%
Sales Q2Q%11.24%
3.2 Future
M12 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.45% yearly.
The Revenue is expected to grow by 7.75% on average over the next years.
EPS Next Y89.39%
EPS Next 2Y47.84%
EPS Next 3Y39.45%
EPS Next 5YN/A
Revenue Next Year12.09%
Revenue Next 2Y9.61%
Revenue Next 3Y9.23%
Revenue Next 5Y7.75%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.82, M12 is valued on the expensive side.
M12's Price/Earnings ratio is in line with the industry average.
M12 is valuated rather cheaply when we compare the Price/Earnings ratio to 28.22, which is the current average of the S&P500 Index.
M12 is valuated correctly with a Price/Forward Earnings ratio of 16.48.
M12's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 20.86. M12 is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.82 | ||
| Fwd PE | 16.48 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as M12.
Based on the Price/Free Cash Flow ratio, M12 is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.97 | ||
| EV/EBITDA | 11.02 |
4.3 Compensation for Growth
M12's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
M12's earnings are expected to grow with 39.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.21
PEG (5Y)3.21
EPS Next 2Y47.84%
EPS Next 3Y39.45%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.05%. Purely for dividend investing, there may be better candidates out there.
M12's Dividend Yield is rather good when compared to the industry average which is at 2.71. M12 pays more dividend than 87.50% of the companies in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y47.84%
EPS Next 3Y39.45%
FRA:M12 (5/2/2025, 7:00:00 PM)
16
-0.42 (-2.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap314.24M
Analysts85
Price Target28.05 (75.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.82 | ||
| Fwd PE | 16.48 | ||
| P/S | 0.94 | ||
| P/FCF | 8.97 | ||
| P/OCF | 8.66 | ||
| P/B | 2.87 | ||
| P/tB | 14.55 | ||
| EV/EBITDA | 11.02 |
EPS(TTM)0.85
EY5.31%
EPS(NY)0.97
Fwd EY6.07%
FCF(TTM)1.78
FCFY11.15%
OCF(TTM)1.85
OCFY11.54%
SpS16.97
BVpS5.57
TBVpS1.1
PEG (NY)0.21
PEG (5Y)3.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.27% | ||
| ROE | 15.32% | ||
| ROCE | 15.68% | ||
| ROIC | 10.98% | ||
| ROICexc | 12.98% | ||
| ROICexgc | 44.89% | ||
| OM | 6.87% | ||
| PM (TTM) | 5.03% | ||
| GM | 17.41% | ||
| FCFM | 10.51% |
ROA(3y)3.84%
ROA(5y)5.12%
ROE(3y)7.69%
ROE(5y)9.05%
ROIC(3y)5.33%
ROIC(5y)5.06%
ROICexc(3y)7.46%
ROICexc(5y)7.66%
ROICexgc(3y)20.1%
ROICexgc(5y)16.58%
ROCE(3y)7.61%
ROCE(5y)7.23%
ROICexcg growth 3Y47.1%
ROICexcg growth 5Y10.13%
ROICexc growth 3Y26.66%
ROICexc growth 5Y-7.94%
OM growth 3Y19.76%
OM growth 5Y-14.29%
PM growth 3Y-8.75%
PM growth 5Y-20.36%
GM growth 3Y-11.67%
GM growth 5Y-14.71%
F-Score8
Asset Turnover1.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.26 | ||
| Cap/Depr | 24.28% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | 16.74 | ||
| Cash Conversion | 129.38% | ||
| Profit Quality | 209.01% | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 4.97 |
F-Score8
WACC7.17%
ROIC/WACC1.53
Cap/Depr(3y)24.3%
Cap/Depr(5y)28.94%
Cap/Sales(3y)0.45%
Cap/Sales(5y)0.8%
Profit Quality(3y)264.65%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)163.63%
EPS 3Y12.51%
EPS 5Y5.87%
EPS Q2Q%189.66%
EPS Next Y89.39%
EPS Next 2Y47.84%
EPS Next 3Y39.45%
EPS Next 5YN/A
Revenue 1Y (TTM)12.05%
Revenue growth 3Y25.61%
Revenue growth 5Y37.14%
Sales Q2Q%11.24%
Revenue Next Year12.09%
Revenue Next 2Y9.61%
Revenue Next 3Y9.23%
Revenue Next 5Y7.75%
EBIT growth 1Y86.59%
EBIT growth 3Y50.43%
EBIT growth 5Y17.54%
EBIT Next Year101.33%
EBIT Next 3Y43.63%
EBIT Next 5YN/A
FCF growth 1Y68.01%
FCF growth 3Y71.63%
FCF growth 5Y106.11%
OCF growth 1Y62.27%
OCF growth 3Y57.15%
OCF growth 5Y48.73%